Study drugs that target immune checkpoints for solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a cancer diagnosis confirmed by a biopsy or tissue test
- You’re 18 or older, and your doctor thinks you may live more than 3 months
- Your condition needs to be considered “measurable” on scans (meets RECIST criteria)
- Your liver and blood counts must be strong enough (specific lab cutoffs for kidney function, blood cells, liver proteins, and clotting tests)
- You must be able to have the planned liver infusion procedure safely (no severe clotting problems, serious kidney failure on dialysis, or certain major heart/artery or blood pressure problems)
- You must use effective birth control if you can become pregnant or father a child, and you must agree to frequent visits and blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial studies whether giving immunotherapy “checkpoint inhibitor” medicine directly into the tumor area (and/or the artery feeding it), along with a chemotherapy-style drug, can work better for advanced solid tumors. It aims to boost the immune system’s ability to attack cancer while still being safe for people with measurable tumors.
This trial tests a combination of immunotherapy drugs given directly into the liver’s blood supply as a first treatment for liver cancer. It aims to see if this approach can shrink tumors and improve outcomes for people with relatively preserved liver function.
This trial tests a new software-guided approach to deliver multiple immunotherapy drugs directly into the liver for people with solid tumors. It aims to see if this method can shrink tumors and improve survival.
This study looks at how certain cancer drugs (called immune checkpoint inhibitors) interact with other medicines in the body. It aims to help doctors understand how to safely combine these treatments.
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.